The McLinns’ Story
Jordan McLinn and his mom Laura share their story of living with
Duchenne muscular dystrophy. Laura describes their decision to
pursue a treatment option and Jordan shares his experiences.
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
For more information about VILTEPSO, talk to your doctor and see Full Prescribing Information.
Even in the face of a serious diagnosis of Duchenne muscular dystrophy, Jordan
continues to see the positives in his life and reminds others that there is hope.